Skip to main content
Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
31.50
+0.59 (1.91%)
Nov 11, 2026, 1:27 PM EST - Market open

Amylyx Pharmaceuticals Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
--87.37380.7922.230.29
Revenue Growth
---77.05%1612.94%7700.00%-56.15%
Gross Profit
-92.43-90.4-141.35227.16-74.21-43.76
Operating Income
-175.73-153.29-255.6838.8-201.34-82.69
Net Income
-163.2-144.74-301.7449.27-198.38-87.93
Earnings Per Share
-1.45-1.53-4.430.70-3.39-13.35
EPS Growth
------

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
768.13316.98176.5371.36346.9596.12
Total Debt
4.945.961.984.246.28-
Net Cash (Debt)
763.19311.02174.52367.13340.6796.12
Net Cash Growth
125.76%78.22%-52.46%7.77%254.43%739.31%
Net Cash Per Share
6.773.292.565.255.8214.59

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-129.88-123.34-167.6511.92-179.87-74.8
Capital Expenditures
-0.14-0.14-36.36-1.24-2.53-0.35
Free Cash Flow
-130.02-123.48-204.0110.68-182.4-75.15
Free Cash Flow Growth
------

Margins
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
---161.78%59.66%--
Operating Margin
---292.63%10.19%-905.72%-29013.33%
Pretax Margin
---345.81%14.26%-888.89%-30852.98%
Profit Margin
---345.36%12.94%-892.38%-30852.98%
FCF Margin
---233.50%2.80%-820.50%-26369.12%

Valuation
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
---20.17--
Forward PE
-6.876.8716.68--
P/FCF Ratio
---93.08--
PS Ratio
--2.952.61110.13-